Adults (n = 10) | Children (n = 11) | |
---|---|---|
Male, n (%) | 7 (70%) | 6 (55%) |
Receiving hydroxyurea, n (%) | 5 (50%) | 6 (55%) |
Interviewed, n (%) | 9 (90%) | 7 (64%) |
Nadir SpO2 < 2 standards below mean for age for people with RDI < 5 [26], n (%) | 9 (90%) | 9 (82%) |
Mean SpO2 < 10th centile (96% [27]), n (%) | 9 (90%) | 9 (82%) |
Nadir SpO2 < 10th centile (93.5% [27]), n (%) | 10 (100%) | 11 (100%) |
Nadir SpO2 < 2.5th centile (85.2% [28]), n (%) | 8 (80%) | 9 (82%) |
Nadir SpO2 < 2 standards below mean (86.8% [29]) , n (%) | 9 (90%) | 9 (82%) |
Age (years), median (range) | 30.2 (18–51.5) | 12 (8.7–16.9) |
Overnight oximetry over 2 nights, median (range) | ||
Mean SpO2 Median (range) | 92.6 (87.7–97.3) | 95.4 (85.0–97.7) |
Nadir SpO2 Median (range) | 79 (65.5–87.4) | 81.1 (73.7–90.7) |
APAP adherence, median (range) | ||
Nights used | 6 (3–7) | 7 (1–7) |
Hours per night over 7 days | 4.12 (0.55–6.77) | 6.18 (0.75–9.19) |
Hours per night over nights used | 5.67 (1.27–7.83) | 6.18 (2.79–9.19) |